- Home
- GSBC vs PHAR Comparison
GSBC vs PHAR Comparison
Compare GSBC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- PHAR
- Stock Information
- Founded
- GSBC 1923
- PHAR 1988
- Country
- GSBC United States
- PHAR Netherlands
- Employees
- GSBC N/A
- PHAR N/A
- Industry
- GSBC Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- PHAR Health Care
- Exchange
- GSBC Nasdaq
- PHAR Nasdaq
- Market Cap
- GSBC 705.4M
- PHAR 618.3M
- IPO Year
- GSBC N/A
- PHAR N/A
- Fundamental
- Price
- GSBC $59.07
- PHAR $8.20
- Analyst Decision
- GSBC Hold
- PHAR Strong Buy
- Analyst Count
- GSBC 2
- PHAR 3
- Target Price
- GSBC $61.00
- PHAR $27.00
- AVG Volume (30 Days)
- GSBC 35.4K
- PHAR 5.6K
- Earning Date
- GSBC 01-21-2025
- PHAR 03-13-2025
- Dividend Yield
- GSBC 2.75%
- PHAR N/A
- EPS Growth
- GSBC N/A
- PHAR N/A
- EPS
- GSBC 5.26
- PHAR N/A
- Revenue
- GSBC $216,992,000.00
- PHAR $285,745,000.00
- Revenue This Year
- GSBC N/A
- PHAR $20.08
- Revenue Next Year
- GSBC $4.75
- PHAR $9.22
- P/E Ratio
- GSBC $11.07
- PHAR N/A
- Revenue Growth
- GSBC N/A
- PHAR 30.64
- 52 Week Low
- GSBC $48.19
- PHAR $6.65
- 52 Week High
- GSBC $68.02
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- GSBC 42.64
- PHAR 36.29
- Support Level
- GSBC $58.79
- PHAR $8.49
- Resistance Level
- GSBC $60.91
- PHAR $9.35
- Average True Range (ATR)
- GSBC 1.97
- PHAR 0.55
- MACD
- GSBC 0.03
- PHAR -0.17
- Stochastic Oscillator
- GSBC 30.76
- PHAR 12.14
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.